Core Insights - Amentum Holdings, Inc. is a prominent provider of specialized technical and operational services, focusing on defense, intelligence, and commercial markets, leveraging advanced technology and domain expertise [1] - The company reported fiscal 2025 revenue of $14.4 billion, adjusted EBITDA of $1.1 billion, and free cash flow of $516 million, indicating strong financial performance for a newly public firm [5] - Amentum's stock price increased by 51% over the past year, significantly outperforming the S&P 500, which rose by approximately 15% [2] Financial Performance - Amentum finished fiscal 2025 with $14.4 billion in revenue, $1.1 billion in adjusted EBITDA, and $516 million in free cash flow, showcasing robust financial health [5] - The company's backlog reached $47 billion with a book-to-bill ratio of 1.2x, providing clear visibility for future revenue [5] - Net leverage decreased to 3.2x, with management projecting further growth in free cash flow for fiscal 2026 [5] Investment Activity - Hyperion Capital Advisors LP acquired an additional 368,521 shares of Amentum Holdings during the third quarter, valued at $10.06 million, representing 5.38% of the fund's U.S. equity holdings [3][4] - The increase in Hyperion's position reflects a strategy to invest in stable, cash-generating businesses rather than high-risk trades [6] Competitive Position - Amentum's diversified contract base and focus on high-value, complex projects enhance its competitive position in the government services sector [1] - The company is positioned alongside other durable businesses in Hyperion's portfolio, indicating a preference for predictability and scale in investments [6]

Core Insights - Bragar Eagel & Squire, P.C. is investigating officers and directors of Driven Brands Holdings, Inc. and Jasper Therapeutics, Inc. on behalf of long-term stockholders due to class action complaints filed against both companies [1][4] Driven Brands Holdings, Inc. (NASDAQ: DRVN) - A class action complaint was filed against Driven Brands on December 22, 2023, alleging that the company made materially false and misleading statements regarding its ability to integrate acquired businesses and the performance of its car wash segment [2][3] - The complaint claims that Driven Brands misrepresented its integration capabilities as a "core strength" and assured investors of "significant progress" in integrating its U.S. auto glass businesses, while downplaying issues related to customer demand in its car wash segment [3] Jasper Therapeutics, Inc. (NASDAQ: JSPR) - A class action complaint was filed against Jasper Therapeutics on September 19, 2025, alleging that the company made materially false and misleading statements about its business operations and compliance policies [4][5] - The complaint highlights that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which increased risks for ongoing studies and overstated the company's financial and clinical prospects [5]